<?xml version="1.0" encoding="UTF-8"?>
<p>The 2019-nCov is genetically similar to the severe acute respiratory syndrome 
 <italic>coronavirus</italic> (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which also belong to the 
 <italic>Coronaviridae</italic> family of viruses, and cause respiratory. The pneumonia caused by the novel coronavirus infection is characterized by fever, cough, dyspnea, and ground-glass-type interstitial changes on radiographical imaging via X-rays and computed tomography scans. On February 5, 2020, the National Health Commission of the People's Republic of China and the National Administration of Traditional Chinese Medicine issued “Guidelines for diagnosis and treatment of novel coronavirus pneumonia (Trial Version 5),”
 <sup>[
  <xref rid="R1" ref-type="bibr">1</xref>]
 </sup> which advocated the use of interferon-alpha (IFN-α), lopinavir/ritonavir (LPV/r) and ribavirin for the treatment of COVID-19.
</p>
